These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33353801)

  • 1. A Decision for Life - Treatment decisions in newly diagnosed families with spinal muscular atrophy (SMA).
    Gusset N; Erbas Y; Germanenko O; Rucinski K; Stumpe E; de Lemus M
    Eur J Paediatr Neurol; 2021 Jan; 30():105-107. PubMed ID: 33353801
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to letter: A decision for life - Treatment decisions in newly diagnosed families with spinal muscular atrophy.
    Kirschner J; Butoianu N; Goemans N; Haberlova J; Kostera-Pruszczyk A; Mercuri E; van der Pol WL; Quijano-Roy S; Sejersen T; Tizzano EF; Ziegler A; Servais L; Muntoni F
    Eur J Paediatr Neurol; 2021 Jan; 30():103-104. PubMed ID: 33640649
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy.
    Pacione M; Siskind CE; Day JW; Tabor HK
    J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community.
    Cruz R; Belter L; Wasnock M; Nazarelli A; Jarecki J
    Clin Ther; 2019 May; 41(5):943-960.e4. PubMed ID: 31056304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parents' Experiences of Information and Decision Making in the Care of Their Child With Severe Spinal Muscular Atrophy: A Population Survey.
    Beernaert K; Lövgren M; Jeppesen J; Werlauff U; Rahbek J; Sejersen T; Kreicbergs U
    J Child Neurol; 2019 Mar; 34(4):210-215. PubMed ID: 30642225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "The Whole Game is Changing and You've Got Hope": Australian Perspectives on Treatment Decision Making in Spinal Muscular Atrophy.
    Farrar MA; Carey KA; Paguinto SG; Kasparian NA; De Abreu Lourenço R
    Patient; 2020 Aug; 13(4):389-400. PubMed ID: 32266662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proximal spinal muscular atrophy (SMA)].
    Fujak A; Wollinsky KH; Forst R
    Z Orthop Unfall; 2007; 145(2):233-52. PubMed ID: 17492565
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnosis and clinical management of spinal muscular atrophy.
    Han JJ; McDonald CM
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):661-80, xii. PubMed ID: 18625423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical aspects of the changing landscape for spinal muscular atrophy management in Australia.
    Newson AJ; Dive L; Cini J; Hurley E; Farrar MA
    Aust J Gen Pract; 2022 Mar; 51(3):131-135. PubMed ID: 35224577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design.
    Finkel RS; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Shieh PB; Tizzano E; Desguerre I; Quijano-Roy S; Saito K; Droege M; Dabbous O; Khan F; Renault L; Anderson FA; Servais L
    J Neuromuscul Dis; 2020; 7(2):145-152. PubMed ID: 32039859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spinal muscular atrophy: diagnosis and management in a new therapeutic era.
    Arnold WD; Kassar D; Kissel JT
    Muscle Nerve; 2015 Feb; 51(2):157-67. PubMed ID: 25346245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinal muscular atrophy: manifestations and management.
    Mesfin A; Sponseller PD; Leet AI
    J Am Acad Orthop Surg; 2012 Jun; 20(6):393-401. PubMed ID: 22661569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy.
    Schwartz M; Likhite S; Meyer K
    Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical practice guidelines for spinal muscular atrophy].
    Writing Group For Practice Guidelines For Diagnosis And Treatment Of Genetic Diseases Medical Genetics Branch Of Chinese Medical Association ; Pan J; Tan H; Zhou M; Liang D; Wu L
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Mar; 37(3):263-268. PubMed ID: 32128742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 190 th ENMC international workshop: Spinal muscular atrophy with respiratory distress/distal spinal muscular atrophy type 1: 11-13 May 2012, Naarden, The Netherlands.
    van der Pol WL; Talim B; Pitt M; von Au K
    Neuromuscul Disord; 2013 Jul; 23(7):602-9. PubMed ID: 23726377
    [No Abstract]   [Full Text] [Related]  

  • 16. Spinal Muscular Atrophy: Past, Present, and Future.
    Ross LF; Kwon JM
    Neoreviews; 2019 Aug; 20(8):e437-e451. PubMed ID: 31371553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population screening for spinal muscular atrophy: A mixed methods study of the views of affected families.
    Boardman FK; Young PJ; Griffiths FE
    Am J Med Genet A; 2017 Feb; 173(2):421-434. PubMed ID: 27792846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput screening reveals novel mutations in spinal muscular atrophy patients.
    Zhang R; Gu C; Pu L; Meng Y; Shu J; Cai C
    Ital J Pediatr; 2020 Nov; 46(1):166. PubMed ID: 33148303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and New Treatment Avenues in Spinal Muscular Atrophy.
    Pechmann A; Kirschner J
    Neuropediatrics; 2017 Aug; 48(4):273-281. PubMed ID: 28571100
    [No Abstract]   [Full Text] [Related]  

  • 20. The need for evidence-based treatment decisions in spinal muscular atrophy type 0.
    Erbas Y; Gusset N
    Ann Clin Transl Neurol; 2021 Oct; 8(10):2094-2095. PubMed ID: 34546649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.